{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:12:54Z","timestamp":1793373174643,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In preterm birth, the immature retina can develop a potentially blinding disorder of the eye known as retinopathy of prematurity (ROP). The vaso-proliferative phase of ROP begins at an approximate postmenstrual age (PMA) of 32\u00a0weeks. There is little or no evidence of an association between ROP development and retinal status in the early vaso-proliferative phase. We aimed to evaluate the retinal vascular findings of infants at 33\u201334\u00a0weeks PMA to determine their risk of ROP. We reviewed 130 serial wide-field retinal images from 65 preterm infants born before the gestational age of 31\u00a0weeks. ROP occurred more frequently in infants having a leading vascular edge within posterior Zone II. This was in contrast to normal infants, who are characterized by complete retinal vascularization up to Zone II at 34\u00a0weeks PMA. The probability of ROP development in preterm infants with retinal edge hemorrhage was 24.58 times higher than in preterm infants without retinal edge hemorrhage. Eyes with ROP that required treatment showed significantly delayed retinal vascularization accompanied by pre-plus disease. In conclusion, retinal status in the early vaso-proliferation phase might determine the risk of ROP.<\/jats:p>","DOI":"10.1038\/s41598-020-75151-0","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T06:03:14Z","timestamp":1603346594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Retinal vascular development in an immature retina at 33\u201334\u00a0weeks postmenstrual age predicts retinopathy of prematurity"],"prefix":"10.1038","volume":"10","author":[{"given":"Ji Hye","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Cheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"75151_CR1","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1056\/NEJMra1208129","volume":"367","author":"ME Hartnett","year":"2012","unstructured":"Hartnett, M. E. & Penn, J. S. Mechanisms and management of retinopathy of prematurity. N. Engl. J. Med. 367, 2515\u20132526 (2012).","journal-title":"N. Engl. J. Med."},{"key":"75151_CR2","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","volume":"382","author":"A Hellstr\u00f6m","year":"2013","unstructured":"Hellstr\u00f6m, A., Smith, L. E. & Dammann, O. Retinopathy of prematurity. Lancet 382, 1445\u20131457 (2013).","journal-title":"Lancet"},{"key":"75151_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1146\/annurev-vision-091517-034018","volume":"15","author":"Y Sun","year":"2018","unstructured":"Sun, Y. & Smith, L. E. Retinal vasculature in development and diseases. Annu. Rev. Vis. Sci. 15, 101\u2013122 (2018).","journal-title":"Annu. Rev. Vis. Sci."},{"key":"75151_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ajo.2006.02.018","volume":"142","author":"JT Flynn","year":"2006","unstructured":"Flynn, J. T. & Chan-Ling, T. Retinopathy of prematurity: Two distinct mechanisms that underlie zone 1 and zone 2 disease. Am. J. Ophthalmol. 142, 46\u201359 (2006).","journal-title":"Am. J. Ophthalmol."},{"key":"75151_CR5","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1007\/s12098-017-2404-3","volume":"84","author":"MR Dogra","year":"2017","unstructured":"Dogra, M. R., Katoch, D. & Dogra, M. An update on retinopathy of prematurity (ROP). Indian J. Pediatr. 84, 930\u2013936 (2017).","journal-title":"Indian J. Pediatr."},{"key":"75151_CR6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1542\/peds.2012-2996","volume":"131","author":"WM Fierson","year":"2013","unstructured":"American Academy of Pediatrics, Fierson, W. M. & American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 131, 189\u2013195 (2013).","journal-title":"Pediatrics"},{"key":"75151_CR7","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s10792-016-0177-8","volume":"36","author":"LA Cernichiaro-Espinosa","year":"2016","unstructured":"Cernichiaro-Espinosa, L. A. et al. New insights in diagnosis and treatment of retinopathy of prematurity. Int. Ophthalmol. 36, 751\u2013760 (2016).","journal-title":"Int. Ophthalmol."},{"key":"75151_CR8","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.oret.2018.02.001","volume":"2","author":"X Chen","year":"2018","unstructured":"Chen, X. et al. Spectral-domain OCT findings of retinal vascular-avascular junction in infants with retinopathy of prematurity. Ophthalmol. Retina 2, 963\u2013971 (2018).","journal-title":"Ophthalmol. Retina"},{"key":"75151_CR9","first-page":"178","volume":"8","author":"N Valikodath","year":"2019","unstructured":"Valikodath, N., Cole, E., Chiang, M. F., Campbell, J. P. & Chan, R. V. P. Imaging in retinopathy of prematurity. Asia Pac. J. Ophthalmol. 8, 178\u2013186 (2019).","journal-title":"Asia Pac. J. Ophthalmol."},{"key":"75151_CR10","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/eye.2015.279","volume":"30","author":"G Kontos","year":"2016","unstructured":"Kontos, G., Khan, A. & Fleck, B. Do we screen very premature babies too early for retinopathy of prematurity?. Eye. 30, 636\u2013637 (2016).","journal-title":"Eye."},{"key":"75151_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/IOP.0000000000000702","volume":"32","author":"HA Tawfik","year":"2016","unstructured":"Tawfik, H. A., Abdulhafez, M. H., Fouad, Y. A. & Dutton, J. J. Embryologic and fetal development of the human eyelid. Ophthal. Plast. Reconstr. Surg. 32, 407\u2013414 (2016).","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"75151_CR12","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/jamaophthalmol.2018.4290","volume":"136","author":"GE Quinn","year":"2018","unstructured":"Quinn, G. E. et al. Incidence and early course of retinopathy of prematurity: Secondary analysis of the postnatal growth and retinopathy of prematurity (G-ROP) study. JAMA Ophthalmol. 136, 1383\u20131389 (2018).","journal-title":"JAMA Ophthalmol."},{"key":"75151_CR13","first-page":"2194","volume":"31","author":"DL Phelps","year":"1990","unstructured":"Phelps, D. L. Oxygen and developmental retinal capillary remodeling in the kitten. Invest. Ophthalmol. Vis. Sci. 31, 2194\u20132200 (1990).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"75151_CR14","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/S0031-3955(16)36370-2","volume":"34","author":"JT Flynn","year":"1987","unstructured":"Flynn, J. T. Retinopathy of prematurity. Pediatr. Clin. N. Am. 34, 1487\u20131516 (1987).","journal-title":"Pediatr. Clin. N. Am."},{"key":"75151_CR15","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S0161-6420(87)33401-3","volume":"94","author":"JT Flynn","year":"1987","unstructured":"Flynn, J. T. et al. Retinopathy of prematurity: Diagnosis, severity and natural history. Ophthalmology 94, 620\u2013629 (1987).","journal-title":"Ophthalmology"},{"key":"75151_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ajo.2015.05.016","volume":"160","author":"A Gschlieber","year":"2015","unstructured":"Gschlieber, A. et al. Inter-expert and intra-expert agreement on the diagnosis and treatment of retinopathy of prematurity. Am. J. Ophthalmol. 160, 553\u2013560 (2015).","journal-title":"Am. J. Ophthalmol."},{"key":"75151_CR17","first-page":"152","volume":"7","author":"L Ghergherehchi","year":"2018","unstructured":"Ghergherehchi, L. et al. Plus disease in retinopathy of prematurity: More than meets the ICROP?. Asia Pac. J. Ophthalmol. 7, 152\u2013155 (2018).","journal-title":"Asia Pac. J. Ophthalmol."},{"key":"75151_CR18","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1001\/jamaophthalmol.2013.135","volume":"131","author":"NJ Hewing","year":"2013","unstructured":"Hewing, N. J., Kaufman, D. R., Chan, V. P. & Chiang, M. F. Plus disease in retinopathy of prematurity: Qualitative analysis of diagnostic process by experts. JAMA Ophthalmol. 131, 1026\u20131032 (2013).","journal-title":"JAMA Ophthalmol."},{"key":"75151_CR19","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","unstructured":"International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch. Ophthalmol. 123, 991\u2013999 (2005).","journal-title":"Arch. Ophthalmol."},{"key":"75151_CR20","first-page":"233","volume":"102","author":"WV Good","year":"2004","unstructured":"Good, W. V. & Early treatment for Retinopathy of Prematurity Cooperative Group. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans. Am. Ophthalmol. Soc. 102, 233\u2013250 (2004).","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"75151_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/IAE.0000000000001126","volume":"37","author":"B Lorenz","year":"2017","unstructured":"Lorenz, B. et al. Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity. Retina 37, 97\u2013111 (2017).","journal-title":"Retina"},{"key":"75151_CR22","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1007\/s10792-018-01064-7","volume":"39","author":"A Vural","year":"2019","unstructured":"Vural, A., Ekinci, D. Y., Onur, I. U., Herg\u00fcnsel, G. O. & Yi\u011fit, F. U. Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression. Int. Ophthalmol. 39, 2267\u20132274 (2019).","journal-title":"Int. Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75151-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75151-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75151-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T16:55:48Z","timestamp":1670345748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75151-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["75151"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-75151-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]},"assertion":[{"value":"3 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.H.J. reports an honorarium from Bayer and Novartis, outside the submitted work. Y.C.K. reports an honorarium from Allergan, Bayer, Novartis and Santen, and a research grant from Bayer, outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18111"}}